Project Details
Description
Project Narrative
Gold standard clinical trials in metastatic melanoma have demonstrated significantly improved survival with
immunotherapy (e.g. immune checkpoint inhibitors; anti-PD1 and anti-PD-L1). However, only about 35% of all
patients benefit and almost all patients eventually develop resistance to immunotherapy and succumb to their
cancer. Stereotactic body radiotherapy is a highly advantageous treatment modality in melanoma due to its
ability to overcome radioresistance and allow patients to mount an immune response against melanoma that
can synergize with immunotherapy, also known as the abscopal effect. Despite these advanced therapies,
melanomas develop resistance by releasing immunosuppressive molecules (sPD-L1 and evPD-L1) in the
blood that kill activated immune cells directed against melanoma. Therefore, we propose to incorporate
therapeutic plasma exchange (a safe and commonly used therapy in patients with autoimmune disease) to
remove immunosuppressive molecules and overcome melanoma therapy resistance and rescue anti-
melanoma immunity brought by radiotherapy and immunotherapy.
Status | Finished |
---|---|
Effective start/end date | 2/5/21 → 1/31/23 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.